Conclusions: Among Japanese patients with previously-treated, unresectable, advanced or recurrent NSCLC, nivolumab showed an almost consistent safety profile with clinical trial data except for frequency of ILD. The benefit-risk profiles should continuously be monitored. Editorial acknowledgement: Content Ed Net. Legal entity responsible for the study: Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb.
Internal Medicine, Mayo Clinic, Rochester, NY, USA Background: Immune-related adverse events (IRAEs) represent a clinical challenge, potentially limiting the clinical benefits of immunotherapy. Data suggests nivolumab and pembrolizumab IRAEs rates are similar but no comparisons across tumor types exist. Therefore, we studied IRAEs in patients (pts) with metastatic melanoma and non-small cell lung cancer (NSCLC) treated with anti-PD1 therapy. Methods: All pts with metastatic melanoma and NSCLC seen at the Mayo Clinic Rochester and Florida from 2015 to 2018 were reviewed. Patients that received prior immunotherapies or thoracic radiation were excluded. Chi-square test was used to estimate differences in categorical data. Results: Out of 510 pts, 266 (52%) had melanoma and 244 (48%) NSCLC. Baseline characteristics were similar across groups, except for sex (NSCLC: 51% women; melanoma: 40% women). 80% of the pts with NSCLC received chemotherapy prior to immunotherapy compared to 14% of the pts with melanoma. 75% (200) of melanoma pts received pembrolizumab and 66% (161) of NSCLC pts received nivolumab. Higher rates of IRAEs were observed in the melanoma pts (55% vs. 41%, <0.001) (Table) . No difference in grade 3 IRAEs was observed. Melanoma pts were more likely to develop diarrhea/colitis and endocrinopathies compared to the NSCLC pts (19% vs. 7%, p < 0.008; 33% vs. 18%, p < 0.01, respectively). Contrarily, pts with NSCLC had higher rates of pneumonitis (14% vs. 6%, p < 0.007). Most pts resumed the anti-PD1 agent after developing IRAEs (60% and 57%, respectively). In 31% of the pts experiencing IRAEs the anti-PD1 agent was permanently discontinue due to toxicity. Conclusions: Patients with metastatic melanoma were more likely to develop IRAEs with anti-PD1 therapy. We observed differences in the IRAEs developed across groups. These associations could be attributed to intrinsic tumor characteristics or differences between anti-PD1 agents. Larger studies are needed to enhance our understanding of these differences. Background: IO has become one of the major pillars of anti-cancer therapy. A range of immune-related adverse events (IRAE) are recognized within various organs. Acute vascular events (AVE) are generally not considered IRAE. Considering the role of inflammation in acute ischemic cardiovascular events, we assumed such events can be triggered by IO. We aimed to evaluate the frequency and nature of AVEs occurring shortly after the initiation of IO. Methods: Computerized search of Sheba medical center (SMC) electronic medical records was done for patients (pts) that received IO (any of: pembrolizumab, nivolumab, atezolizumab, ipilimumab). Out of those, we searched for cases with a diagnosis of AVE within 1 month after initiation of IO. Search was for the diagnoses: cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarct (MI), non-ST-elevation MI, ST-elevation MI, embolic event, pulmonary emboli (PE) and deep vein thrombosis (DVT). We excluded cases with AVE within a year prior to the initiation of therapy, concomitant chemotherapy, and cases of a single-site DVT. Results: Between 1st January 2015 and 14th March 2018, 1396 pts received IO in SMC. 14 pts were identified in the computerized search. Excluded: 4 with a single site DVT, 1 with a prior cardiovascular event within a year prior to initiation of IO, 1 with concomitant chemotherapy, 3 excluded due to AVE not definitely diagnosed, leaving 5 pts not excluded. 8 additional pts were identified by reports of physicians aware of this project, of these 2 were also identified by the computerized search, thus a total of 11 pts fit our study criteria. Events were: multiple CVA (3), PE (2), sudden cardiac death (2), bilateral DVT (1), CVA (1), TIA (1), MI (1). In one pt marantic endocarditis was suspected. 7 pts had diabetes, 7 pts had hypertension, 2 pts had a body mass index > 30, 3 were smoking within < 10 years ago, none had a family history of cardiovascular disease. 9 of the pts were treated in SMC, constituting a frequency of 0.6%. Conclusions: AVEs occur at a low frequency shortly after initiation of IO. Initiation of IO may be the trigerring event of those events. Further retrospective studies and analyses of clinical trials data are required to evaluate whether this is a random association or a true IRAE. Background: Pembrolizumab (PEM), a humanized antibody targeting programmed death-1 receptor, has been approved by FDA for the treatment of patients (pts) with advanced melanoma (AM) in the US for over 3 years. The study examined the realworld (RW) use of PEM and associated patient (pt) outcomes in the US Oncology Clinical Practices. Methods: Flatiron Health longitudinal database was used to identify adult pts with AM who received 1 dose of PEM between September 4, 2014 and December 31, 2016. These pts were followed up to December 31, 2017. Pts in clinical trials were excluded. Pt demographic, treatment, and clinical characteristics were described. Time on treatment (ToT) and overall survival (OS) were analyzed using the Kaplan Meier (KM) method, with the first dose of any PEM as the starting point. 
